♥

Hester Biosciences Limited

ISIN : INE782E01017
NSE : HESTERBIO
BSE : 524669
Face Value : 10
Industry : Pharmaceuticals & Drugs

EPS : 24.88
EPS (TTM) : 30.91
Price to Earning (P/E) : 50.42
Book Value : 343.00
Price to Bookvalue (P/B) : 3.66
Dividend Yield : 0 %
Return on Equity (ROE) : 7.41 %
Return on Capital Employed (ROCE) : 9.59 %

Hester Biosciences share price (02-Apr-2026)
National Stock Exchange NSE
Open / Close	0 - 0 NAN %
Low / High	0 - 0 NAN %
Trade Volume	0
52 Week Low / High	0 - 0 NAN %
Bombay Stock Exchange BSE
Open / Close	1348.1 - 1427.9 5.9 %
Low / High	1336.9 - 1432.05 7.1 %
Trade Volume	341
52 Week Low / High	1250.95 - 2347.7 87.7 %

YOU MAY ALSO LIKE

High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE
CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator
Share Market basics for beginners
Share Market jargons in simple terms
How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
Stock market course tutorial
Stock Market Investment Course explained in simple words.

Consolidated Standalone

CONSOLIDATED QUARTERLY RESULT FOR HESTER BIOSCIENCES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	506.95	731.53	749.44	672.99	878.53	704.55	669.83	792.55	822.67	836.92
Total Income	538.18	776.02	793.35	704.87	889.98	748.13	679.73	834	834.92	855.32
Total Expenditure	432.65	604.08	561.85	556.24	734.9	572.4	568.28	633.33	646.17	645.32
Other Income	31.23	44.49	43.91	31.88	11.45	43.58	9.9	41.45	12.25	18.4
Operating Profit	105.53	171.94	231.5	148.63	155.08	175.73	111.45	200.67	188.75	210
Interest	16.01	24.55	38.9	13.74	25.68	80.75	21.93	69.39	50.09	58.86
PBDT	89.52	147.39	192.6	134.89	129.4	94.98	89.52	131.28	138.66	151.14
Depreciation	50.6	50.3	52.4	53.65	53.99	42.84	37.49	37.42	41.34	42.01
Profit Before Tax	38.92	97.09	140.2	81.24	75.41	52.14	52.03	93.86	97.32	109.13
Tax	19.03	36.69	38.4	27.07	22.02	27.22	23.91	34.72	31.06	34.77
Profit After Tax	19.89	60.4	101.8	54.17	53.39	24.92	28.12	59.14	66.26	74.36
Net Profit	19.89	60.4	101.8	54.17	53.39	24.92	28.12	59.14	66.26	74.36
Equity Capital	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	4.66	8.16	13.15	5.33	6.9	4.8	4.68	5.82	7.45	9.64
Diluted Eps After Extraordinary Items	4.19	7.77	14.29	6.72	7.89	4.75	4.73	7.52	8.8	9.86
Diluted Eps Before Extraordinary Items	4.19	7.77	14.29	6.72	7.89	4.75	4.73	7.52	8.8	9.86

STANDALONE QUARTERLY RESULT FOR HESTER BIOSCIENCES LIMITED

Date End	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
No of months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months	3 months
Net Sales	505.28	720.03	707.73	606.96	803.45	664.33	655.05	728.72	734.66	735.02
Total Income	517.62	741.8	717.35	616.46	812.04	676.53	664.85	740.75	745.23	748.48
Total Expenditure	413.3	562.21	517.86	497.77	689.8	544.4	539.37	604.57	599.69	587.71
Other Income	12.34	21.77	9.62	9.5	8.59	12.2	9.8	12.03	10.57	13.46
Operating Profit	104.32	179.59	199.49	118.69	122.24	132.13	125.48	136.18	145.54	160.77
Interest	12.69	17.43	31.37	3.48	9.42	14.75	13.66	13.1	11.26	14.02
PBDT	91.63	162.16	168.12	115.21	112.82	117.38	111.82	123.08	134.28	146.75
Depreciation	23.93	23.37	24.37	26.21	25.48	25.78	25.69	20.83	21.23	21.94
Profit Before Tax	67.7	138.79	143.75	89	87.34	91.6	86.13	102.25	113.05	124.81
Tax	17.65	35.34	36.46	26.37	22.63	23.78	21.38	27.94	28.73	31.45
Profit After Tax	50.05	103.45	107.29	62.63	64.71	67.82	64.75	74.31	84.32	93.36
Net Profit	50.05	103.45	107.29	62.63	64.71	67.82	64.75	74.31	84.32	93.36
Equity Capital	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07	85.07
Face Value (IN RS)	10	10	10	10	10	10	10	10	10	10
Calculated EPS	5.88	12.16	12.61	7.36	7.61	7.97	7.61	8.74	9.91	10.97
Diluted Eps After Extraordinary Items	5.88	12.16	12.61	7.36	7.61	7.97	7.61	8.74	9.91	10.97
Diluted Eps Before Extraordinary Items	5.88	12.16	12.61	7.36	7.61	7.97	7.61	8.74	9.91	10.97

Consolidated Standalone

CONSOLIDATED ANNUAL RESULT FOR HESTER BIOSCIENCES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	2350.06	2660.91	3045.46
Total Income	2487.47	2812.42	3151.84
Total Expenditure	1750.23	2154.82	2508.91
Other Income	137.41	151.51	106.38
Operating Profit	737.24	657.6	642.93
Interest	40.64	93.2	197.75
PBDT	696.6	564.4	445.18
Depreciation	165.81	206.95	171.74
Profit Before Tax	530.79	357.45	273.44
Tax	140.18	121.19	107.87
Profit After Tax	390.61	236.26	165.57
Net Profit	390.61	236.26	165.57
Equity Capital	85.07	85.07	85.07
Face Value (IN RS)	10	10	10
Reserves	2514.78	2712.23	2832.86
Calculated EPS	46.22	31.3	22.2
Diluted Eps After Extraordinary Items	46.41	32.96	24.88
Diluted Eps Before Extraordinary Items	46.41	32.96	24.88

STANDALONE ANNUAL RESULT FOR HESTER BIOSCIENCES LIMITED

Date End	Mar 2022	Mar 2023	Mar 2024
No of months	12 months	12 months	12 months
Net Sales	2193.51	2540	2851.55
Total Income	2240.08	2593.23	2894.17
Total Expenditure	1587.82	1991.14	2378.14
Other Income	46.57	53.23	42.62
Operating Profit	652.26	602.09	516.03
Interest	24.68	64.97	50.93
PBDT	627.58	537.12	465.1
Depreciation	95.02	97.88	97.78
Profit Before Tax	532.56	439.24	367.32
Tax	137.39	115.82	95.73
Profit After Tax	395.17	323.42	271.59
Net Profit	395.17	323.42	271.59
Equity Capital	85.07	85.07	85.07
Face Value (IN RS)	10	10	10
Reserves	2599.27	2838.75	3042.05
Calculated EPS	46.45	38.02	31.93
Diluted Eps After Extraordinary Items	46.45	38.02	31.93
Diluted Eps Before Extraordinary Items	46.45	38.02	31.93

Consolidated Standalone

CONSOLIDATED PROFIT / LOSS FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	214.33 Cr	235.01 Cr	268.01 Cr	304.78 Cr
Sales	196.76 Cr	231.11 Cr	263.1 Cr	301.81 Cr
Processing Charges / Service Income	93.3 Lk	20 Lk	0	0
Net Sales	214.33 Cr	235.01 Cr	266.09 Cr	304.55 Cr
Increase/Decrease in Stock	3.6 Cr	-10.56 Cr	-5.25 Cr	8.74 Cr
Raw Material Consumed	46.62 Cr	73.27 Cr	82.74 Cr	87.14 Cr
Opening Raw Materials	7.91 Cr	9.43 Cr	10.91 Cr	9.35 Cr
Purchases Raw Materials	40.18 Cr	62.13 Cr	54.69 Cr	52.67 Cr
Closing Raw Materials	9.43 Cr	10.91 Cr	12.62 Cr	7.7 Cr
Other Direct Purchases / Brought in cost	7.97 Cr	12.62 Cr	29.75 Cr	32.82 Cr
Power & Fuel Cost	7.57 Cr	10.28 Cr	12.74 Cr	15.3 Cr
Electricity & Power	7.57 Cr	10.28 Cr	12.74 Cr	15.3 Cr
Employee Cost	38.92 Cr	45.33 Cr	56.02 Cr	64.13 Cr
Salaries, Wages & Bonus	36.76 Cr	42.67 Cr	53.39 Cr	60.61 Cr
Contributions to EPF & Pension Funds	1.34 Cr	1.8 Cr	1.91 Cr	2.51 Cr
Workmen and Staff Welfare Expenses	25.2 Lk	30.4 Lk	32.3 Lk	55.8 Lk
Other Manufacturing Expenses	11.6 Cr	13.36 Cr	12.67 Cr	17.13 Cr
Repairs and Maintenance	1.77 Cr	2.34 Cr	3.72 Cr	2.24 Cr
General and Administration Expenses	15.29 Cr	19.49 Cr	24.89 Cr	27.17 Cr
Rent , Rates & Taxes	2.43 Cr	1.64 Cr	2.25 Cr	3.53 Cr
Insurance	80.8 Lk	3.18 Cr	1.23 Cr	1.22 Cr
Professional and legal fees	5.15 Cr	4.23 Cr	4.09 Cr	3.53 Cr
Traveling and conveyance	5.9 Cr	9.47 Cr	15.78 Cr	16.92 Cr
Selling and Distribution Expenses	15.02 Cr	17.31 Cr	26.34 Cr	25.6 Cr
Advertisement & Sales Promotion	0	4.96 Cr	9.97 Cr	8.81 Cr
Sales Commissions & Incentives	0	1.36 Cr	3.16 Cr	3.27 Cr
Freight and Forwarding	9.38 Cr	10.99 Cr	13.21 Cr	13.52 Cr
Miscellaneous Expenses	7.06 Cr	6.53 Cr	5.54 Cr	6.18 Cr
Bad debts /advances written off	69 Lk	1.99 Cr	34.3 Lk	51.2 Lk
Provision for doubtful debts	0	47.1 Lk	39.2 Lk	69 Lk
Loss on foreign exchange fluctuations	40.3 Lk	0	0	0
Total Expenditure	145.67 Cr	175.02 Cr	215.69 Cr	251.38 Cr
Other Income	4.68 Cr	13.74 Cr	15.36 Cr	11.13 Cr
Interest Received	1.29 Cr	1.9 Cr	2.17 Cr	1.91 Cr
Profit on sale of Fixed Assets	1.5 Lk	12.5 Lk	1.6 Lk	2.8 Lk
Provision Written Back	0	0	20.7 Lk	49 Lk
Foreign Exchange Gains	0	7.2 Lk	84.8 Lk	87.8 Lk
Operating Profit	73.34 Cr	73.72 Cr	65.76 Cr	64.29 Cr
Interest	6.6 Cr	4.06 Cr	9.32 Cr	19.78 Cr
Bank Charges etc	54.2 Lk	95.7 Lk	33.1 Lk	31 Lk
PBDT	66.74 Cr	69.66 Cr	56.44 Cr	44.52 Cr
Depreciation	13.31 Cr	16.58 Cr	20.7 Cr	17.17 Cr
Profit Before Taxation & Exceptional Items	53.42 Cr	53.08 Cr	35.74 Cr	27.34 Cr
Exceptional Income / Expenses	-3.32 Cr	0	0	0
Profit Before Tax	50.1 Cr	53.08 Cr	40.15 Cr	31.95 Cr
Provision for Tax	15.4 Cr	14.02 Cr	12.12 Cr	10.79 Cr
Current Income Tax	16.95 Cr	14.78 Cr	11.28 Cr	10.73 Cr
Deferred Tax	-1.54 Cr	-76.6 Lk	84.1 Lk	6.1 Lk
Profit After Tax	34.7 Cr	39.06 Cr	28.04 Cr	21.17 Cr
Minority Interest	-26.8 Lk	-16.4 Lk	-1.41 Cr	-2.28 Cr
Share of Associate	0	42.3 Lk	0	0
Consolidated Net Profit	34.43 Cr	39.32 Cr	26.63 Cr	18.89 Cr
Profit Balance B/F	125.22 Cr	154.11 Cr	184.81 Cr	203.04 Cr
Appropriations	159.65 Cr	193.43 Cr	211.44 Cr	221.93 Cr
Other Appropriation	5.4 Cr	8.62 Cr	8.4 Cr	6.84 Cr
Equity Dividend %	100	100	80	60
Earnings Per Share	40.47	46.22	31.3	22.2
Adjusted EPS	40.47	46.22	31.3	22.2

STANDALONE PROFIT / LOSS FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Gross Sales	208.48 Cr	219.35 Cr	255.92 Cr	285.39 Cr
Sales	190.9 Cr	215.5 Cr	251.01 Cr	283.69 Cr
Processing Charges / Service Income	93.3 Lk	20 Lk	0	0
Net Sales	208.48 Cr	219.35 Cr	254 Cr	285.16 Cr
Increase/Decrease in Stock	4.01 Cr	-12.53 Cr	-4.77 Cr	10.36 Cr
Raw Material Consumed	49.38 Cr	74.23 Cr	84.65 Cr	89.28 Cr
Opening Raw Materials	5.76 Cr	6.02 Cr	7.2 Cr	6.65 Cr
Purchases Raw Materials	24.44 Cr	36.11 Cr	31.38 Cr	31.66 Cr
Closing Raw Materials	6.02 Cr	7.2 Cr	9.31 Cr	5.62 Cr
Other Direct Purchases / Brought in cost	25.21 Cr	39.3 Cr	55.37 Cr	56.6 Cr
Power & Fuel Cost	6.93 Cr	8.74 Cr	9.94 Cr	12.34 Cr
Electricity & Power	6.93 Cr	8.74 Cr	9.94 Cr	12.34 Cr
Employee Cost	33.45 Cr	39.12 Cr	47.92 Cr	56.72 Cr
Salaries, Wages & Bonus	31.62 Cr	37.4 Cr	45.79 Cr	53.92 Cr
Contributions to EPF & Pension Funds	1.15 Cr	1.31 Cr	1.67 Cr	2.2 Cr
Workmen and Staff Welfare Expenses	11.5 Lk	7.7 Lk	9.7 Lk	19.5 Lk
Other Manufacturing Expenses	10.79 Cr	12.02 Cr	10.54 Cr	15.2 Cr
Repairs and Maintenance	1.52 Cr	1.98 Cr	2.26 Cr	1.62 Cr
General and Administration Expenses	13.24 Cr	14.78 Cr	21.6 Cr	24.92 Cr
Rent , Rates & Taxes	1.83 Cr	1 Cr	1.64 Cr	2.98 Cr
Insurance	66.5 Lk	65.1 Lk	93.6 Lk	91.3 Lk
Professional and legal fees	4.24 Cr	3.45 Cr	2.74 Cr	2.86 Cr
Traveling and conveyance	5.54 Cr	8.53 Cr	14.83 Cr	16.46 Cr
Selling and Distribution Expenses	13.96 Cr	17.16 Cr	24.68 Cr	24.63 Cr
Advertisement & Sales Promotion	5.3 Cr	4.89 Cr	9.82 Cr	8.66 Cr
Sales Commissions & Incentives	0	1.28 Cr	3.14 Cr	3.27 Cr
Freight and Forwarding	8.67 Cr	10.98 Cr	11.73 Cr	12.69 Cr
Miscellaneous Expenses	4.71 Cr	7.22 Cr	4.76 Cr	4.86 Cr
Bad debts /advances written off	69 Lk	1.99 Cr	34.3 Lk	51.2 Lk
Provision for doubtful debts	0	2.18 Cr	39.2 Lk	69 Lk
Loss on foreign exchange fluctuations	40.3 Lk	0	0	0
Total Expenditure	136.48 Cr	160.74 Cr	199.32 Cr	238.3 Cr
Other Income	1.65 Cr	6.61 Cr	5.53 Cr	4.75 Cr
Interest Received	26.2 Lk	1.9 Cr	2.09 Cr	1.91 Cr
Profit on sale of Fixed Assets	1.5 Lk	12.5 Lk	1.6 Lk	2.8 Lk
Profits on sale of Investments	0	22.6 Lk	0	0
Provision Written Back	0	1.96 Cr	20.7 Lk	49 Lk
Foreign Exchange Gains	0	92 Lk	1.29 Cr	44.2 Lk
Operating Profit	73.64 Cr	65.23 Cr	60.21 Cr	51.6 Cr
Interest	3.95 Cr	2.47 Cr	6.5 Cr	5.09 Cr
Bank Charges etc	23.2 Lk	54.3 Lk	23.4 Lk	20.3 Lk
PBDT	69.69 Cr	62.76 Cr	53.71 Cr	46.51 Cr
Depreciation	9.63 Cr	9.5 Cr	9.79 Cr	9.78 Cr
Profit Before Taxation & Exceptional Items	60.06 Cr	53.26 Cr	43.92 Cr	36.73 Cr
Exceptional Income / Expenses	-5.28 Cr	0	0	0
Profit Before Tax	54.78 Cr	53.26 Cr	43.92 Cr	36.73 Cr
Provision for Tax	14.88 Cr	13.74 Cr	11.58 Cr	9.57 Cr
Current Income Tax	16.36 Cr	14.25 Cr	10.73 Cr	9.64 Cr
Deferred Tax	-1.48 Cr	-51.4 Lk	85.5 Lk	-6.2 Lk
Profit After Tax	39.9 Cr	39.52 Cr	32.34 Cr	27.16 Cr
Consolidated Net Profit	39.9 Cr	39.52 Cr	32.34 Cr	27.16 Cr
Profit Balance B/F	136.9 Cr	171.4 Cr	202.25 Cr	226.2 Cr
Appropriations	176.8 Cr	210.92 Cr	234.59 Cr	253.36 Cr
Other Appropriation	5.4 Cr	8.66 Cr	8.39 Cr	6.83 Cr
Equity Dividend %	100	100	80	60
Earnings Per Share	46.9	46.45	38.02	31.93
Adjusted EPS	46.9	46.45	38.02	31.93

Consolidated Standalone

CONSOLIDATED CASH FLOW FOR HESTER BIOSCIENCES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	50.1 Cr	53.5 Cr	40.15 Cr	31.95 Cr
Adjustment	22.66 Cr	11.1 Cr	12.39 Cr	24.22 Cr
Changes In working Capital	-77.6 Lk	-38.68 Cr	-20.84 Cr	3.62 Cr
Cash Flow after changes in Working Capital	71.99 Cr	25.92 Cr	31.7 Cr	59.8 Cr
Cash Flow from Operating Activities	58.05 Cr	8.81 Cr	23.6 Cr	48.13 Cr
Cash Flow from Investing Activities	-38.37 Cr	-116.59 Cr	-77 Cr	-22.65 Cr
Cash Flow from Financing Activitie	-18.22 Cr	111.61 Cr	41.76 Cr	-26.04 Cr
Net Cash Inflow / Outflow	1.46 Cr	3.83 Cr	-11.64 Cr	-56.5 Lk
Opening Cash & Cash Equivalents	23.53 Cr	21.27 Cr	24.75 Cr	13.16 Cr
Effect of Foreign Exchange Fluctuations	-3.72 Cr	-34.9 Lk	5.1 Lk	15.7 Lk
Closing Cash & Cash Equivalent	21.27 Cr	24.75 Cr	13.16 Cr	12.75 Cr

STANDALONE CASH FLOW FOR HESTER BIOSCIENCES LIMITED

Year End	Mar 2021	Mar 2022	Mar 2023	Mar 2024
No of Months	12 months	12 months	12 months	12 months
Profit Before Tax	54.78 Cr	53.26 Cr	43.92 Cr	36.73 Cr
Adjustment	18.58 Cr	11.7 Cr	14.55 Cr	13.32 Cr
Changes In working Capital	-19.8 Cr	-32.61 Cr	-17.05 Cr	3.79 Cr
Cash Flow after changes in Working Capital	53.56 Cr	32.34 Cr	41.43 Cr	53.84 Cr
Cash Flow from Operating Activities	40.07 Cr	15.9 Cr	33.36 Cr	42.81 Cr
Cash Flow from Investing Activities	-2.69 Cr	-110.58 Cr	-71.96 Cr	-20.63 Cr
Cash Flow from Financing Activitie	-41.32 Cr	94.96 Cr	41.38 Cr	-24.07 Cr
Net Cash Inflow / Outflow	-3.95 Cr	28.4 Lk	2.77 Cr	-1.89 Cr
Opening Cash & Cash Equivalents	5.19 Cr	1.24 Cr	1.53 Cr	4.3 Cr
Closing Cash & Cash Equivalent	1.24 Cr	1.53 Cr	4.3 Cr	2.41 Cr

Consolidated Standalone

CONSOLIDATED BALANCE SHEET FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Equity - Authorised	11.2 Cr	11.2 Cr	11.2 Cr	11.2 Cr
Equity - Issued	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Equity Paid Up	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Face Value	10	10	10	10
Total Reserves	219.8 Cr	251.48 Cr	271.22 Cr	283.29 Cr
Securities Premium	17.51 Cr	17.51 Cr	17.51 Cr	17.51 Cr
Capital Reserves	8.26 Cr	8.26 Cr	8.26 Cr	8.26 Cr
Profit & Loss Account Balance	154.25 Cr	184.81 Cr	203.04 Cr	215.09 Cr
General Reserves	39.23 Cr	39.23 Cr	39.23 Cr	39.23 Cr
Reserve excluding Revaluation Reserve	219.8 Cr	251.48 Cr	271.22 Cr	283.29 Cr
Shareholder's Funds	228.31 Cr	259.98 Cr	279.73 Cr	291.79 Cr
Minority Interest	7.65 Cr	7.41 Cr	8.82 Cr	11.08 Cr
Secured Loans	82.84 Cr	164.54 Cr	184.85 Cr	181.77 Cr
Term Loans - Banks	100.79 Cr	28.14 Cr	21.97 Cr	36.59 Cr
Deferred Tax Assets / Liabilities	7.28 Cr	6.51 Cr	7.35 Cr	7.41 Cr
Deferred Tax Assets	34.9 Lk	75.4 Lk	1.01 Cr	1.22 Cr
Deferred Tax Liability	7.62 Cr	7.26 Cr	8.36 Cr	8.63 Cr
Other Long Term Liabilities	23.61 Cr	25.54 Cr	38.59 Cr	61.97 Cr
Long Term Provisions	0	1.27 Cr	1.93 Cr	2.53 Cr
Total Non-Current Liabilities	113.72 Cr	197.87 Cr	232.72 Cr	253.69 Cr
Trade Payables	28.09 Cr	18.02 Cr	29.98 Cr	26.44 Cr
Sundry Creditors	28.09 Cr	18.02 Cr	29.98 Cr	26.44 Cr
Other Current Liabilities	22.52 Cr	42.81 Cr	55.96 Cr	44.78 Cr
Advances received from customers	44.4 Lk	64.9 Lk	7.96 Cr	98.9 Lk
Interest Accrued But Not Due	0	24.4 Lk	17.3 Lk	34.7 Lk
Current maturity - Others	10.7 Lk	8.79 Cr	12.8 Lk	0
Short Term Borrowings	3.28 Cr	34.84 Cr	58.86 Cr	31.35 Cr
Secured ST Loans repayable on Demands	3.28 Cr	34.84 Cr	58.86 Cr	31.35 Cr
Working Capital Loans- Sec	3.28 Cr	34.84 Cr	58.86 Cr	31.35 Cr
Short Term Provisions	7.48 Cr	1.22 Cr	3.9 Cr	3.22 Cr
Provision for Tax	3.08 Cr	93.8 Lk	3.4 Cr	2.46 Cr
Total Current Liabilities	61.37 Cr	96.9 Cr	148.7 Cr	105.78 Cr
Total Liabilities	411.05 Cr	562.16 Cr	669.97 Cr	662.35 Cr
Gross Block	228.12 Cr	348.16 Cr	385.8 Cr	382.04 Cr
Less: Accumulated Depreciation	95.36 Cr	110.99 Cr	126.43 Cr	141.93 Cr
Net Block	132.76 Cr	237.17 Cr	259.37 Cr	240.11 Cr
Capital Work in Progress	108.99 Cr	80.22 Cr	146.14 Cr	168.11 Cr
Non Current Investments	0	21.24 Cr	25.3 Cr	29.93 Cr
Long Term Investment	0	21.24 Cr	25.3 Cr	29.93 Cr
Unquoted	0	21.24 Cr	25.3 Cr	29.93 Cr
Long Term Loans & Advances	4.98 Cr	24.22 Cr	7.67 Cr	5.55 Cr
Other Non Current Assets	2.81 Cr	2.86 Cr	1.43 Cr	73.7 Lk
Total Non-Current Assets	249.54 Cr	367.4 Cr	442.37 Cr	447.73 Cr
Unquoted	0	21.24 Cr	25.3 Cr	29.93 Cr
Inventories	62.22 Cr	75.38 Cr	84.81 Cr	75.58 Cr
Raw Materials	4.95 Cr	7.97 Cr	9.35 Cr	7.7 Cr
Work-in Progress	28.74 Cr	14.78 Cr	15.08 Cr	12.6 Cr
Finished Goods	13.9 Cr	41.6 Cr	38.46 Cr	35.08 Cr
Packing Materials	4.49 Cr	2.95 Cr	3.27 Cr	4.58 Cr
Stores and Spare	1.36 Cr	1.47 Cr	4.23 Cr	3.76 Cr
Sundry Debtors	49.21 Cr	55.28 Cr	79.63 Cr	78.64 Cr
Debtors more than Six months	0	13.23 Cr	14.92 Cr	14.66 Cr
Debtors Others	49.5 Cr	42.68 Cr	65.41 Cr	64.88 Cr
Cash and Bank	21.27 Cr	25.2 Cr	14.82 Cr	15.3 Cr
Cash in hand	1.18 Cr	46.3 Lk	61.8 Lk	1.31 Cr
Balances at Bank	20.09 Cr	24.74 Cr	14.2 Cr	13.99 Cr
Other Current Assets	2.56 Cr	5.2 Cr	6.02 Cr	5.81 Cr
Interest accrued and or due on loans	12.4 Lk	1.76 Cr	3.43 Cr	3.44 Cr
Prepaid Expenses	98.7 Lk	2.39 Cr	1.28 Cr	1.27 Cr
Short Term Loans and Advances	26.24 Cr	33.7 Cr	42.32 Cr	39.27 Cr
Advances recoverable in cash or in kind	78.5 Lk	7.08 Cr	9.63 Cr	7.06 Cr
Total Current Assets	161.51 Cr	194.76 Cr	227.59 Cr	214.62 Cr
Net Current Assets (Including Current Investments)	100.14 Cr	97.87 Cr	78.9 Cr	108.83 Cr
Total Assets	411.05 Cr	562.16 Cr	669.97 Cr	662.35 Cr
Contingent Liabilities	14.8 Lk	14.8 Lk	19.8 Lk	0
Total Debt	104.52 Cr	222.57 Cr	268.15 Cr	239.04 Cr
Book Value	268.38	305.61	328.82	343
Adjusted Book Value	268.38	305.61	328.82	343

STANDALONE BALANCE SHEET FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Share Capital	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Equity - Authorised	11.2 Cr	11.2 Cr	11.2 Cr	11.2 Cr
Equity - Issued	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Equity Paid Up	8.51 Cr	8.51 Cr	8.51 Cr	8.51 Cr
Face Value	10	10	10	10
Total Reserves	229.07 Cr	259.93 Cr	283.88 Cr	304.2 Cr
Securities Premium	17.51 Cr	17.51 Cr	17.51 Cr	17.51 Cr
Capital Reserves	94.2 Lk	94.2 Lk	94.2 Lk	94.2 Lk
Profit & Loss Account Balance	171.4 Cr	202.25 Cr	226.2 Cr	246.53 Cr
General Reserves	39.23 Cr	39.23 Cr	39.23 Cr	39.23 Cr
Reserve excluding Revaluation Reserve	229.07 Cr	259.93 Cr	283.88 Cr	304.2 Cr
Shareholder's Funds	237.58 Cr	268.43 Cr	292.38 Cr	312.71 Cr
Secured Loans	2.68 Cr	73.25 Cr	83.4 Cr	79.07 Cr
Term Loans - Banks	13.8 Cr	20 Cr	18.26 Cr	32.76 Cr
Deferred Tax Assets / Liabilities	6.81 Cr	6.29 Cr	7.15 Cr	7.08 Cr
Deferred Tax Assets	31.4 Lk	46.1 Lk	71.9 Lk	96.3 Lk
Deferred Tax Liability	7.12 Cr	6.75 Cr	7.87 Cr	8.05 Cr
Other Long Term Liabilities	30.3 Lk	55.3 Lk	24.7 Cr	50.7 Cr
Long Term Provisions	0	1.08 Cr	1.72 Cr	2.26 Cr
Total Non-Current Liabilities	9.78 Cr	81.17 Cr	116.96 Cr	139.11 Cr
Trade Payables	14.02 Cr	11.03 Cr	28.71 Cr	30.12 Cr
Sundry Creditors	14.02 Cr	11.03 Cr	28.71 Cr	30.12 Cr
Other Current Liabilities	15.1 Cr	29.34 Cr	46.59 Cr	35.14 Cr
Advances received from customers	44.4 Lk	64.9 Lk	7.94 Cr	38 Lk
Interest Accrued But Not Due	0	24.4 Lk	17.3 Lk	34.7 Lk
Current maturity - Others	10.7 Lk	8.79 Cr	12.8 Lk	0
Short Term Borrowings	1.71 Cr	33.29 Cr	57.34 Cr	29.79 Cr
Secured ST Loans repayable on Demands	1.71 Cr	33.29 Cr	57.34 Cr	29.79 Cr
Working Capital Loans- Sec	1.71 Cr	33.29 Cr	57.34 Cr	29.79 Cr
Short Term Provisions	3.81 Cr	1.18 Cr	3.83 Cr	2.67 Cr
Provision for Tax	2.94 Cr	93.8 Lk	3.39 Cr	2 Cr
Total Current Liabilities	34.65 Cr	74.84 Cr	136.47 Cr	97.72 Cr
Total Liabilities	282.02 Cr	424.44 Cr	545.82 Cr	549.55 Cr
Gross Block	164.64 Cr	171.17 Cr	199 Cr	203.62 Cr
Less: Accumulated Depreciation	77.95 Cr	86.86 Cr	90.78 Cr	100.16 Cr
Net Block	86.69 Cr	84.31 Cr	108.22 Cr	103.46 Cr
Capital Work in Progress	3.54 Cr	80.22 Cr	146.14 Cr	168.11 Cr
Non Current Investments	43.88 Cr	64.69 Cr	64.69 Cr	64.69 Cr
Long Term Investment	43.88 Cr	64.69 Cr	64.69 Cr	64.69 Cr
Unquoted	43.88 Cr	64.69 Cr	64.69 Cr	64.69 Cr
Long Term Loans & Advances	5.5 Cr	24.2 Cr	6.83 Cr	4.85 Cr
Other Non Current Assets	2.8 Cr	2.86 Cr	1.43 Cr	73.7 Lk
Total Non-Current Assets	142.41 Cr	257.97 Cr	329.77 Cr	345.13 Cr
Unquoted	43.88 Cr	64.69 Cr	64.69 Cr	64.69 Cr
Inventories	57.01 Cr	70.73 Cr	79.22 Cr	68.53 Cr
Raw Materials	2.91 Cr	5.39 Cr	6.65 Cr	5.62 Cr
Work-in Progress	28.74 Cr	14.78 Cr	15.05 Cr	12.52 Cr
Finished Goods	12.1 Cr	32.77 Cr	28.35 Cr	25.49 Cr
Packing Materials	3.11 Cr	1.81 Cr	2.66 Cr	3.38 Cr
Stores and Spare	1.36 Cr	1.37 Cr	2.98 Cr	2.96 Cr
Sundry Debtors	45.55 Cr	56.92 Cr	82.36 Cr	85.78 Cr
Debtors more than Six months	0	16.89 Cr	17.56 Cr	21.43 Cr
Debtors Others	45.84 Cr	40.54 Cr	65.5 Cr	65.25 Cr
Cash and Bank	1.24 Cr	1.98 Cr	5.96 Cr	4.96 Cr
Cash in hand	12.1 Lk	24.8 Lk	27.5 Lk	18.2 Lk
Balances at Bank	1.12 Cr	1.73 Cr	5.69 Cr	4.78 Cr
Other Current Assets	6.3 Cr	2.83 Cr	5.45 Cr	5.36 Cr
Interest accrued and or due on loans	12.4 Lk	1.76 Cr	3.43 Cr	3.44 Cr
Prepaid Expenses	86.8 Lk	46.8 Lk	1.1 Cr	1.19 Cr
Short Term Loans and Advances	29.5 Cr	34.01 Cr	43.06 Cr	39.78 Cr
Advances recoverable in cash or in kind	4.4 Cr	8.42 Cr	11.13 Cr	8.32 Cr
Total Current Assets	139.61 Cr	166.47 Cr	216.05 Cr	204.41 Cr
Net Current Assets (Including Current Investments)	104.96 Cr	91.64 Cr	79.58 Cr	106.69 Cr
Total Assets	282.02 Cr	424.44 Cr	545.82 Cr	549.55 Cr
Contingent Liabilities	103.05 Cr	106.44 Cr	115.24 Cr	116.77 Cr
Total Debt	15.9 Cr	121.91 Cr	164.32 Cr	133.56 Cr
Book Value	279.28	315.55	343.7	367.59
Adjusted Book Value	279.28	315.55	343.7	367.59

Consolidated Standalone

FINANCIAL RATIOS (CONSOLIDATED) FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	40.47	46.22	31.3	22.2
CEPS(Rs)	56.44	65.41	57.28	45.07
DPS(Rs)	10	10	8	6
Book NAV/Share(Rs)	268.38	305.61	328.82	343
Tax Rate(%)	30.75	26.41	30.18	33.76
Margin Ratios
Core EBITDA Margin(%)	32.03	25.52	18.81	17.44
EBIT Margin(%)	26.46	24.32	18.46	16.97
Pre Tax Margin(%)	23.38	22.59	14.98	10.48
PAT Margin (%)	16.19	16.62	10.46	6.94
Cash Profit Margin (%)	22.4	23.68	18.18	12.58
Performance Ratios
ROA(%)	8.7	8.03	4.55	3.18
ROE(%)	16.16	16	10.39	7.41
ROCE(%)	17.33	14.02	9.6	9.59
Asset Turnover(x)	0.54	0.48	0.44	0.46
Sales/Fixed Asset(x)	0.94	0.82	0.73	0.79
Working Capital/Sales(x)	2.14	2.4	3.4	2.8
Efficiency Ratios
Fixed Capital/Sales(x)	1.06	1.23	1.37	1.26
Receivable days	91.66	81.15	91.87	94.77
Inventory Days	107.45	106.86	109.08	96.04
Payable days	60.64	134.17	113.04	107.38
Valuation Parameters
PER(x)	47.36	58.75	48.58	62.57
PCE(x)	33.96	41.51	26.54	30.83
Price/Book(x)	7.14	8.88	4.62	4.05
Yield(%)	0.52	0.37	0.53	0.43
EV/Net Sales(x)	8	10.67	5.81	4.62
EV/Core EBITDA(x)	23.37	34.01	23.52	21.86
EV/EBIT(x)	30.22	43.88	31.26	27.17
EV/CE(x)	4.17	4.46	2.31	2.65
M Cap / Sales	7.61	9.83	4.86	3.88
Growth Ratio
Net Sales Growth(%)	16.95	9.65	13.23	14.45
Core EBITDA Growth(%)	18.74	0.52	-10.8	-2.23
EBIT Growth(%)	16.45	0.77	-14.06	4.56
PAT Growth(%)	11.92	12.57	-29	-24.5
EPS Growth(%)	18.03	14.2	-32.28	-29.06
Financial Stability Ratios
Total Debt/Equity(x)	0.46	0.86	0.96	0.82
Current Ratio(x)	2.63	2.01	1.53	2.03
Quick Ratio(x)	1.62	1.23	0.96	1.31
Interest Cover(x)	8.59	14.06	5.31	2.62
Total Debt/Mcap(x)	0.06	0.1	0.21	0.2

FINANCIAL RATIOS (STANDALONE) FOR HESTER BIOSCIENCES LIMITED

YEAR	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Operational & Financial Ratios
Earnings Per Share (Rs)	46.9	46.45	38.02	31.93
CEPS(Rs)	58.23	57.62	49.52	43.42
DPS(Rs)	10	10	8	6
Book NAV/Share(Rs)	279.28	315.55	343.7	367.59
Tax Rate(%)	27.17	25.8	26.37	26.06
Margin Ratios
Core EBITDA Margin(%)	34.53	26.72	21.37	16.42
EBIT Margin(%)	28.17	25.4	19.7	14.66
Pre Tax Margin(%)	26.28	24.28	17.16	12.87
PAT Margin (%)	19.14	18.02	12.64	9.52
Cash Profit Margin (%)	23.76	22.35	16.46	12.94
Performance Ratios
ROA(%)	14.27	11.19	6.67	4.96
ROE(%)	18.11	15.62	11.53	8.98
ROCE(%)	23.28	17.31	11.91	9.26
Asset Turnover(x)	0.75	0.62	0.53	0.52
Sales/Fixed Asset(x)	1.26	1.31	1.38	1.42
Working Capital/Sales(x)	1.99	2.39	3.22	2.67
Efficiency Ratios
Fixed Capital/Sales(x)	0.79	0.77	0.72	0.71
Receivable days	79.06	85.25	99.32	107.52
Inventory Days	102.81	106.29	106.93	94.48
Payable days	37.15	74.1	90.79	107.75
Valuation Parameters
PER(x)	40.87	58.45	39.99	43.52
PCE(x)	32.92	47.12	30.7	32
Price/Book(x)	6.86	8.61	4.42	3.78
Yield(%)	0.52	0.37	0.53	0.43
EV/Net Sales(x)	7.89	11.08	5.72	4.6
EV/Core EBITDA(x)	22.34	37.25	24.11	25.39
EV/EBIT(x)	28.01	43.6	28.79	31.33
EV/CE(x)	5.83	5.72	2.66	2.94
M Cap / Sales	7.82	10.53	5.09	4.14
Growth Ratio
Net Sales Growth(%)	23.05	5.22	15.8	12.27
Core EBITDA Growth(%)	32.33	-11.43	-7.69	-14.29
EBIT Growth(%)	26.95	-5.12	-9.52	-17.05
PAT Growth(%)	27.79	-0.96	-18.16	-16.03
EPS Growth(%)	27.79	-0.96	-18.16	-16.03
Financial Stability Ratios
Total Debt/Equity(x)	0.07	0.45	0.56	0.43
Current Ratio(x)	4.03	2.22	1.58	2.09
Quick Ratio(x)	2.38	1.28	1	1.39
Interest Cover(x)	14.88	22.58	7.76	8.21
Total Debt/Mcap(x)	0.01	0.05	0.13	0.11

SHARE HOLDING PATTERN FOR HESTER BIOSCIENCES LIMITED

Date	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoters %	44.28	44.28	44.28	44.28	44.28	44.28	44.28	44.28	44.28	44.28
FII %	0.72	0.00	0.45	0.45	0.45	0.42	0.43	0.43	0.52	0.61
DII %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Public %	45.51	45.61	45.78	45.82	45.82	45.85	45.84	45.84	45.74	45.66

PEER COMPARISON FOR HESTER BIOSCIENCES LIMITED

No.	Name
1	AMBALAL SARABHAI ENTERPRISES LTD
2	Cipla Limited
3	Dr. Reddy's Laboratories Limited
4	Procter & Gamble Health Limited
5	J.K.PHARMACHEM LTD
6	Lupin Limited
7	Lyka Labs Limited
8	MESCO PHARMACEUTICALS LTD
9	Morepen Laboratories Limited
10	Piramal Enterprises Limited
11	Torrent Pharmaceuticals Limited
12	Abbott India Limited
13	GlaxoSmithKline Pharmaceuticals Limited
14	Sanofi India Limited
15	Pfizer Limited
16	Bliss GVS Pharma Limited
17	Alembic Limited
18	Unichem Laboratories Limited
19	AstraZeneca Pharma India Limited
20	GUJARAT THEMIS BIOSYN LTD
21	JB Chemicals & Pharmaceuticals Limited
22	TTK Healthcare Limited
23	Jagsonpal Pharmaceuticals Limited
24	Gufic Biosciences Limited
25	Sequent Scientific Limited
26	Albert David Limited
27	IOL Chemicals and Pharmaceuticals Limited
28	Wanbury Limited
29	Kopran Limited
30	Aarti Drugs Limited
31	Orchid Pharma Limited
32	Biofil Chemicals & Pharmaceuticals Limited
33	Marksans Pharma Limited
34	IPCA Laboratories Limited
35	Kilitch Drugs (India) Limited
36	Krebs Biochemicals and Industries Limited
37	Neuland Laboratories Limited
38	Ind-Swift Limited
39	Hester Biosciences Limited
40	Parenteral Drugs (India) Limited
41	Sun Pharmaceutical Industries Limited
42	Hikal Limited
43	Caplin Point Laboratories Limited
44	Aurobindo Pharma Limited
45	Natco Pharma Limited
46	Bal Pharma Limited
47	BDH INDUSTRIES LTD
48	Venus Remedies Limited
49	Jubilant Pharmova Limited
50	Themis Medicare Limited

CORPORATE ACTIONS FOR HESTER BIOSCIENCES

Exchange Date	Purpose	Book Closure Dates
BSE 21-Oct-2024	Board Meeting - Quarterly Results	28-Oct-2024
BSE 26-Jul-2024	Book Closure - Rs.6.0000 per share(60%)Dividend & A.G.M.	23-Aug-2024 29-Aug-2024
BSE 26-Jul-2024	AGM - Rs.6.0000 per share(60%)Dividend & A.G.M.	29-Aug-2024 29-Aug-2024
BSE 25-Jul-2024	Board Meeting - Quarterly Results	02-Aug-2024
BSE 10-May-2024	Dividend - Rs.6.0000 per share(60%)Dividend
BSE 02-May-2024	Board Meeting - Dividend & Audited Results	10-May-2024
BSE 24-Jan-2024	Board Meeting - Quarterly Results	02-Feb-2024
BSE 27-Oct-2023	Board Meeting - Quarterly Results	07-Nov-2023
BSE 23-Aug-2023	Book Closure - Rs.8.0000 per share(80%)Final Dividend & A.G.M.	14-Sep-2023 20-Sep-2023
BSE 23-Aug-2023	AGM - Rs.8.0000 per share(80%)Final Dividend & A.G.M.	20-Sep-2023 20-Sep-2023
BSE 31-Jul-2023	Board Meeting - Quarterly Results	08-Aug-2023
BSE 17-May-2023	Dividend - Rs.8.0000 per share(80%)Final Dividend
BSE 09-May-2023	Board Meeting - Final Dividend & Audited Results	17-May-2023
BSE 24-Jan-2023	Board Meeting - Quarterly Results	31-Jan-2023
BSE 25-Oct-2022	Board Meeting - Quarterly Results	04-Nov-2022
BSE 02-Aug-2022	Board Meeting - Quarterly Results	10-Aug-2022
BSE 29-Jul-2022	Book Closure - Rs.10.0000 per share(100%)Dividend & A.G.M.	13-Aug-2022 23-Aug-2022
BSE 29-Jul-2022	AGM - Rs.10.0000 per share(100%)Dividend & A.G.M.	13-Aug-2022 23-Aug-2022
BSE 20-May-2022	Dividend - Rs.10.0000 per share(100%)Dividend
BSE 12-May-2022	Board Meeting - Dividend & Audited Results	20-May-2022
BSE 20-Jan-2022	Board Meeting - Quarterly Results	31-Jan-2022
BSE 10-Nov-2021	Board Meeting - Inter alia, to consider the borrowings of additional funds as a loan to meeting capex and investment requirements of the Company.	13-Nov-2021
BSE 09-Nov-2021	SAST - We would like to inform that Hester Biosciences Limited (Hester India) has entered into a Shareholder's Agreement, Share Purchase Agreement and Share Subscription Agreement (collectively referred to as Transactional Documents) to: 1.Acquire 486 equity shares of Thrishool Exim Limited (TEL), Tanzania from the existing promoters 2.Subscribe 1,188 equity shares of TEL Thereby, acquire and subscribe a...
BSE 20-Oct-2021	Board Meeting - Quarterly Results	28-Oct-2021

CORPORATE ANNOUNCEMENTS FOR HESTER BIOSCIENCES

Exchange Date	Category File	Description
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Pursuant to Regulations 30 and 46(2)(oa) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached the transcript of the earnings conference call held by the management of the Company with investors on Monday 28 October 2024 at 2:00 p.m. (IST) to discuss the financial results for the for the quarter and six months period ended 30 September 2024. This is for your information and records.
BSE 30-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) Intimation of Resignation of Chief Financial Officer under Regulation 30 of SEBI (LODR) Regulations 2015
BSE 29-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper advertisement of Financial Results
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio recording of the Companys earnings conference call on the financial results for the for the quarter and six months period ended 30 September 2024 is available on the Companys website: www.hester.in
BSE 28-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release 20241028 Q2/H1 FY25 Press Release
BSE 28-Oct-2024	Outcome FILE	Financial Results For The Period Ended 30 September 2024 Financial Results for the period ended 30 September 2024
BSE 28-Oct-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Outcome of Board Meeting
BSE 24-Oct-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform that the Company has scheduled investor interaction through a teleconference call on Monday 28 October 2024 at 2:00 p.m. (IST) post the announcement of financial results for the quarter and six months period ended 30 September 2024. Details for joining the call are attached herewith.
BSE 21-Oct-2024	Intimation FILE	Board Meeting Intimation for Financial Results HESTER BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter and six months period ended 30 September 2024.
BSE 10-Oct-2024	General Announcements FILE	Intimation Regarding Receipt Of Audit Report From GST Department Ahmedabad Intimation regarding receipt of Special Audit Report from GST Department Ahmedabad for the period from April 2018 to March 2023
BSE 09-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Details of Loss of Certificate requests received from the shareholder.
BSE 09-Oct-2024	General Announcements FILE	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended 30 September 2024
BSE 07-Oct-2024	General Announcements FILE	Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate
BSE 25-Sep-2024	Intimation FILE	Closure of Trading Window Closure of Trading Winow
BSE 29-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting results and scrutinizer report of 37th Annual General Meeting
BSE 29-Aug-2024	Outcome FILE	Shareholder Meeting / Postal Ballot-Outcome of AGM Outcome Proceedings Voting Results and Scrutinizer report of 37th Annual General Meeting held on 29 August 2024
BSE 05-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Transcript of Earnings Conference Call held on 2 August 2024
BSE 05-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication of Financial Results Q1FY25
BSE 02-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Audio recording of the Earnings Conference Call
BSE 02-Aug-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Press Release / Media Release 20240802 Q1FY25 Press Release
BSE 02-Aug-2024	Outcome FILE	Financial Results Q1 FY25 Financial Results Q1 FY25
BSE 02-Aug-2024	Outcome FILE	Board Meeting Outcome for Outcome Of Board Meeting Held On 2 August 2024 Outcome of Board Meeting
BSE 27-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Clipping - Notice of the 37th Annual General Meeting of the Company
BSE 27-Jul-2024	General Announcements FILE	Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of earnings conference call on Friday 2 August 2024 at 2:00 p.m. (IST) post the announcement of financial results for the quarter ended 30 June 2024.
BSE 26-Jul-2024	General Announcements FILE	Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report for the year ended 31 March 2024
BSE 26-Jul-2024	Intimation FILE	Record Date For The Dividend Payment And Annual General Meeting 22 August 2024 will be the record date for the payment of dividend and Cut off date for the AGM. The Board of Directors at the meeting led on 10 May 2024 have recommended INR 6 per share for the financial year 2023-24 subject to approval of Members at the ensuing annual general meeting
BSE 26-Jul-2024	Intimation FILE	Book Closure For Dividend And AGM The Register of Members and Share transfer Books of the Company will remain closed from 23 August 2024 to 29 August 2024 (Both days inclusive) for the purpose of Payment of Dividend and 37th Annual General Meeting of the Company schedule to be held on 29 August 2024 Record date will be 22 August 2024. Thursday 22 August 2024 will be cut-off date for the purpose of determining the Members eligible to vote on the resolutions set out in the Notice of the AGM or to attend the AGM and Dividend Payments.
BSE 26-Jul-2024	General Announcements FILE	Reg. 34 (1) Annual Report. Hesters 37th Annual Report 2023-24
BSE 26-Jul-2024	Intimation FILE	37Th Annual General Meeting Of The Company Pursuant to Regulation 30 and 34(1) of SEBI (LODR) Regulations 2015 we are submitting herewith the 37th Annual General Meeting along with the Annual Report of the Company for the year 2023-24 which is being sent to the Members of the Company through electronic means as per the circulars issued by the Ministry of Corporate Affairs and SEBI.37th Annual General Meeting schedule to be held on Thursday 29 August 2024 through video conference/ other audio visual means. Thursday 22 August 2024 will be the "Cut-off Date" for the purpose of determining the Members eligible to vote on resolutions set out in the Notice of the AGM or to attend the AGM.
BSE 25-Jul-2024	Intimation FILE	Board Meeting Intimation for Financial Results HESTER BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2024 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended 30 June 2024.

INSIDER TRADING FOR HESTER BIOSCIENCES

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
BSE 06-Feb-2023 06-Feb-2023	Buy Others	301,600 @ 0.00 (3.55 %)	SHAILA BHUPENDRA GANDHI
BSE 06-Feb-2023 06-Feb-2023	Sell Others	301,600 @ 0.00 (0.00 %)	BHUPENDRA VITHALDAS GANDHI HUF

BULK BLOCK DEALS FOR HESTER BIOSCIENCES LIMITED

Exchange Dates	Activity	Qty & Price (%)	Person / Organisation
No Bulk Block details found

DIVIDEND BY HESTER BIOSCIENCES LIMITED

Ex Dividend Date	Dividend Type	Dividend
22-Aug-2024	DIVIDEND	6
13-Sep-2023	DIVIDEND	8
11-Aug-2022	DIVIDEND	10
05-Aug-2021	DIVIDEND	10

SPLIT / BONUS BY HESTER BIOSCIENCES LIMITED

No Split / Bonus details found

Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed

Facebook

Twitter

To TOP

Hester Biosciences Limited

Hester Biosciences share price

CONSOLIDATED QUARTERLY RESULT FOR HESTER BIOSCIENCES LIMITED

STANDALONE QUARTERLY RESULT FOR HESTER BIOSCIENCES LIMITED

CONSOLIDATED ANNUAL RESULT FOR HESTER BIOSCIENCES LIMITED

STANDALONE ANNUAL RESULT FOR HESTER BIOSCIENCES LIMITED

CONSOLIDATED PROFIT / LOSS FOR HESTER BIOSCIENCES LIMITED

STANDALONE PROFIT / LOSS FOR HESTER BIOSCIENCES LIMITED

CONSOLIDATED CASH FLOW FOR HESTER BIOSCIENCES LIMITED

STANDALONE CASH FLOW FOR HESTER BIOSCIENCES LIMITED

CONSOLIDATED BALANCE SHEET FOR HESTER BIOSCIENCES LIMITED

STANDALONE BALANCE SHEET FOR HESTER BIOSCIENCES LIMITED

FINANCIAL RATIOS (CONSOLIDATED) FOR HESTER BIOSCIENCES LIMITED

FINANCIAL RATIOS (STANDALONE) FOR HESTER BIOSCIENCES LIMITED

SHARE HOLDING PATTERN FOR HESTER BIOSCIENCES LIMITED

PEER COMPARISON FOR HESTER BIOSCIENCES LIMITED

CORPORATE ACTIONS FOR HESTER BIOSCIENCES

CORPORATE ANNOUNCEMENTS FOR HESTER BIOSCIENCES

INSIDER TRADING FOR HESTER BIOSCIENCES

BULK BLOCK DEALS FOR HESTER BIOSCIENCES LIMITED

DIVIDEND BY HESTER BIOSCIENCES LIMITED

SPLIT / BONUS BY HESTER BIOSCIENCES LIMITED